

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 -16 (Canceled)

Claim 17 (Currently Amended): A method of treating a patient infected with hepatitis B virus and HIV comprising administering to the patient a nucleotide prodrug of β -L-2',3'-dideoxyadenosine (β -L-DDA) or a pharmaceutically acceptable salt or prodrug thereof, in combination with a second compound selected from:

- a) 3'-azido-3'-deoxythymidine (AZT),
- b) 2',3'-dideoxyinosine (DDI),
- c) 2',3'-dideoxy-2',3'-didehydrothymidine (D4T),
- d) 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC),
- e) ~~a non-nucleoside RT inhibitor~~ a Tibo compound, nevirapine, or a pyrimidinone, or
- f) a physiologically acceptable salt ~~or prodrug~~ thereof.

Claim 18 (Currently Amended): The method of claim 17 wherein the nucleotide prodrug of β -L-2',3'-dideoxyadenosine (β -L-DDA) is administered in enantiomerically enriched form.

Claim 19 -20 (Cancelled)

Claim 21 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide is a monophosphate.

Claim 22 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide is a diphosphate.

Claim 23 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide is a triphosphate.

Claim 24 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is an alkylated nucleotide.

Claim 25 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is an acylated nucleotide.

Claim 26 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is a lipophilic derivative of the nucleotide.

Claim 27 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is a derivative in which one or more hydrogens in the phosphate moiety of the nucleotide is replaced by an alkyl.

Claim 28 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is a derivative in which one or more hydrogens in the phosphate moiety of the nucleotide is replaced by a steroid.

Claim 29 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is a derivative in which one or more hydrogens in the phosphate moiety of the nucleotide is replaced by a carbohydrate.

Claim 30 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is a derivative in which one or more hydrogens in the phosphate moiety of the nucleotide is replaced by a sugar.

Claim 31 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is a derivative in which one or more hydrogens in the phosphate moiety of the nucleotide is replaced by a 1,2-diacylglycerol.

Claim 32 (New): The method of claim 17, wherein the β -L-2',3'-dideoxyadenosine nucleotide prodrug is a derivative in which one or more hydrogens in the phosphate moiety of the nucleotide is replaced by an alcohol.

Claim 33 (New): The method of claim 17, wherein the prodrug component of the nucleotide increases the activity of the nucleoside in vivo.

Claim 34. (New): The method of claim 17, wherein the second compound is 3'-azido-3'-deoxythymidine (AZT).

Claim 35. (New): The method of claim 17, wherein the second compound is 2',3'-dideoxyinosine (DDI).

Claim 36. (New): The method of claim 17, wherein the second compound is 2',3'-dideoxy-2',3'-didehydrothymidine (D4T).

Claim 37. (New): The method of claim 17, wherein the second compound is 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC).

Claim 38. (New): The method of claim 17, wherein the second compound is a Tibo compound.

Claim 39. (New): The method of claim 17, wherein the second compound is nevirapine.

Claim 40. (New): The method of claim 17, wherein the second compound is a pyrimidinone.

Claim 41. (New): The method of claim 17, wherein the second compound is a physiologically acceptable salt of a nucleotide prodrug of β -L-2',3'-dideoxyadenosine (β -L-DDA).